PT 141 for women is FDA-approved as Vyleesi for low sexual desire. Learn how it works, how fast it kicks in, dosing, and side effects to expect.
PT-141 (bremelanotide) is a prescription-only drug that the FDA approved in 2019 as Vyleesi for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). It is injected under the skin at least 45 minutes before sexual activity and works on brain pathways tied to desire rather than on hormones. PT-141 helps some women and does nothing for others, and it is not a treatment for pain with sex, relationship strain, or menopause-related dryness.
What PT-141 Is — and What It Is Not
PT-141 is a synthetic peptide derived from melanotan II, an unapproved tanning drug. Researchers noticed that melanotan II increased sexual desire as a side effect, and bremelanotide was developed from that observation.
Unlike testosterone or estrogen therapy, PT-141 does not raise hormone levels in the blood. It activates melanocortin receptors in the central nervous system, which are believed to influence desire and arousal.
Bremelanotide is the generic name and Vyleesi is the brand name. Only the Vyleesi autoinjector is FDA-approved for human use in women.
| Product | What it is | US regulatory status | Typical dose |
|---|---|---|---|
| Vyleesi (bremelanotide) | Single-use autoinjector pen | FDA-approved, prescription only | 1.75 mg under the skin, as needed |
| Compounded bremelanotide | Pharmacy-mixed injection or nasal spray | Not FDA-approved | Varies by pharmacy |
| Research-grade PT-141 | Lyophilized powder sold online | Not approved for human use | No standard exists |
How Fast Does PT-141 Work for Women?
A common question is how fast does pt-141 work for women, and the prescribing information gives a clear answer: about 45 minutes after the injection.
Effects usually fade within a few hours, and the drug is taken as needed rather than on a daily schedule. PT-141 does not build up in the body, so skipping days does not reduce its effect.
The label sets three limits:
- Inject at least 45 minutes before anticipated sexual activity.
- Use no more than one dose in 24 hours.
- Use no more than eight doses in a month.
Taking extra doses does not produce a stronger response and increases the odds of nausea.
PT-141 Dosing: 1.75 mg Approved vs. 10 mg Vials
The FDA-approved dose for women is 1.75 mg injected under the skin. Any clinic or website quoting a much larger number is describing something other than the approved product.
Searches that include pt-141 10mg dosage women typically lead to lyophilized peptide vials, which arrive as a powder the buyer must mix with bacteriostatic water. Those vials are labeled for laboratory research only, and mixing at home introduces dosing errors, contamination, and uncertainty about what the vial actually contains.
Men are not covered by the FDA approval. Researchers studying pt 141 dosage for men use protocols that remain experimental, and results in men have not been reviewed by the agency.
| Parameter | FDA-approved use (women) | Common off-label practice |
|---|---|---|
| Dose | 1.75 mg subcutaneous | 1–2 mg, sometimes higher |
| Timing | At least 45 minutes before activity | Varies widely |
| Frequency cap | 1 per 24 hours, max 8 per month | Frequently exceeded |
| Oversight | Prescription and licensed pharmacy | Self-mixed, unregulated |
In clinical trials, 1.75 mg produced the best balance of benefit and side effects, and higher doses were not more effective.
Side Effects, Blood Pressure, and Skin Changes
Nausea is the most common reaction, followed by flushing and headache. Most reactions are mild to moderate and resolve within a few hours of the injection.
| Side effect | Approximate rate in trials |
|---|---|
| Nausea | About 40% |
| Flushing | About 20% |
| Injection site reactions | About 13% |
| Headache | About 11% |
| Vomiting | About 5% |
A full list of pt-141 for women side effects appears in the Vyleesi prescribing information, including fatigue, dizziness, and nasal congestion.
Bremelanotide temporarily raises blood pressure and heart rate, with readings peaking one to two hours after the injection. It is contraindicated in women with uncontrolled high blood pressure or known cardiovascular disease.
Repeated use can cause focal hyperpigmentation — dark patches on the face, gums, breasts, or other areas — and those patches may not fade after the drug is stopped.
Anyone considering PT-141 should review medications and health history with a healthcare professional, especially if they take blood pressure medication or have a heart condition. PT-141 is not recommended during pregnancy or breastfeeding.
Does PT-141 Actually Work? What the Trials Show
Two Phase 3 trials known as RECONNECT enrolled roughly 1,200 premenopausal women with HSDD. About 25% of women taking bremelanotide reported a meaningful improvement in desire, compared with about 17% taking a placebo.
Average improvements on desire and distress scores were modest, and the drug did not work for everyone. Roughly one in four women responds well, so a fair trial of several doses is the only reliable way to know whether it will help.
Bremelanotide has also been studied in postmenopausal women and in men, but the FDA approval covers premenopausal women with acquired, generalized HSDD only.
PT-141 is not a cure for low desire, and clinicians often pair it with counseling or treatment for underlying causes such as depression, medication side effects, or ongoing relationship stress.
Where Women Get PT-141 — and Why Research Peptides Are Risky
Vyleesi requires a prescription, and many women get it through a telehealth visit, a gynecologist, or a sexual medicine clinic. Compounding pharmacies also prepare bremelanotide, but compounded drugs are not FDA-approved.
Sites with pt 141 peptide for sale usually market the powder as a research chemical and add a 'not for human consumption' disclaimer. Independent testing has found that some of these products contain less peptide than the label claims or carry bacterial contamination.
PT-141 sold online as a research chemical is not FDA-approved for human use, and injecting an unverified powder carries real risks of infection and dosing errors.
The Bottom Line
PT-141, sold as Vyleesi, is a legitimate prescription option for premenopausal women with persistent low sexual desire that causes distress. It works for roughly one in four women, takes about 45 minutes to kick in, and commonly causes nausea, flushing, and headache. Women with uncontrolled high blood pressure or heart disease should not use it, and a clinician should review other options first.
Frequently Asked Questions
Is PT-141 FDA-approved for women?
Yes. Bremelanotide was approved in 2019 under the brand name Vyleesi for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). It is not approved for men, for postmenopausal women, or for any other condition.
How fast does PT-141 work, and how long do the effects last?
PT-141 is injected at least 45 minutes before sexual activity, and effects typically begin around that time. The drug wears off within a few hours, and use is limited to one dose every 24 hours and no more than eight doses per month.
Can I buy PT-141 without a prescription?
No. Vyleesi is a prescription-only product in the United States, so it requires a consultation with a licensed clinician. Powders sold online as research-grade PT-141 are not FDA-approved for human use and have no guaranteed strength or sterility.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.